Expand OCGN Menu
OCGN MENU

OCGN Latest Press Releases

-- January 21, 2026 --

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock Globe Newswire 8:32 AM

-- January 15, 2026 --

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Globe Newswire 8:15 AM

-- January 13, 2026 --

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data Globe Newswire 7:00 AM

-- January 12, 2026 --

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy Globe Newswire 6:30 AM

-- January 9, 2026 --

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference Globe Newswire 7:02 AM

-- December 10, 2025 --

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit Globe Newswire 9:20 AM

-- November 20, 2025 --

Ocugen CEO to Present at NobleCon21-Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference Globe Newswire 7:02 AM

-- November 5, 2025 --

Ocugen Provides Business Update with Third Quarter 2025 Financial Results Globe Newswire 6:30 AM

-- October 23, 2025 --

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results Globe Newswire 7:30 AM

-- October 2, 2025 --

Ocugen to Present at Industry and Investor Conferences in October 2025 Globe Newswire 7:30 AM

-- September 15, 2025 --

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea Globe Newswire 6:03 AM

-- September 2, 2025 --

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025 Globe Newswire 7:02 AM
Market Data Delayed 15 Minutes